Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

111 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A customized pigmentation SNP array identifies a novel SNP associated with melanoma predisposition in the SLC45A2 gene.
Ibarrola-Villava M, Fernandez LP, Alonso S, Boyano MD, Peña-Chilet M, Pita G, Aviles JA, Mayor M, Gomez-Fernandez C, Casado B, Martin-Gonzalez M, Izagirre N, De la Rua C, Asumendi A, Perez-Yarza G, Arroyo-Berdugo Y, Boldo E, Lozoya R, Torrijos-Aguilar A, Pitarch A, Pitarch G, Sanchez-Motilla JM, Valcuende-Cavero F, Tomas-Cabedo G, Perez-Pastor G, Diaz-Perez JL, Gardeazabal J, Martinez de Lizarduy I, Sanchez-Diez A, Valdes C, Pizarro A, Casado M, Carretero G, Botella-Estrada R, Nagore E, Lazaro P, Lluch A, Benitez J, Martinez-Cadenas C, Ribas G. Ibarrola-Villava M, et al. Among authors: carretero g. PLoS One. 2011 Apr 29;6(4):e19271. doi: 10.1371/journal.pone.0019271. PLoS One. 2011. PMID: 21559390 Free PMC article.
One-year safety and efficacy of ustekinumab and results of dose adjustment after switching from inadequate methotrexate treatment: the TRANSIT randomized trial in moderate-to-severe plaque psoriasis.
Reich K, Puig L, Paul C, Kragballe K, Luger T, Lambert J, Chimenti S, Girolomoni G, Nicolas JF, Rizova E, Brunori M, Mistry S, Bergmans P, Barker J; TRANSIT Investigators. Reich K, et al. Br J Dermatol. 2014 Feb;170(2):435-44. doi: 10.1111/bjd.12643. Br J Dermatol. 2014. PMID: 24116868 Clinical Trial.
Dose reduction is a feasible strategy in patients with plaque psoriasis who achieve sustained response with secukinumab: a retrospective, multicenter cohort study in daily practice setting.
Daudén E, Escario E, Martos-Cabrera L, Armesto S, Herrera-Acosta E, Vidal D, Vilarrasa E, Rivera R, de la Cueva P, Martorell A, Ballesca F, Belinchón I, Carretero G, Rodríguez L, Romero-Maté A, Pujol-Montcusí J, Salgado L, Sahuquillo-Torralba A, Coto-Segura P, Baniandrés O, Feltes R, Riera-Monroig J, Garrido J, Llamas-Velasco M. Daudén E, et al. Among authors: carretero g. Int J Dermatol. 2024 Apr;63(4):503-511. doi: 10.1111/ijd.16915. Epub 2024 Jan 2. Int J Dermatol. 2024. PMID: 38168847
Efficacy and Safety of Dimethyl Fumarate in Patients with Moderate-to-Severe Plaque Psoriasis: Results from a 52-Week Open-Label Phase IV Clinical Trial (DIMESKIN 1).
Daudén E, de la Cueva P, Salgado-Boquete L, Llamas-Velasco M, Fonseca E, Pau-Charles I, Asensio D, Guilà M, Carrascosa JM; DIMESKIN 1 Study investigators. Daudén E, et al. Dermatol Ther (Heidelb). 2023 Jan;13(1):329-345. doi: 10.1007/s13555-022-00863-2. Epub 2022 Dec 1. Dermatol Ther (Heidelb). 2023. PMID: 36456890 Free PMC article.
Drug Survival in Cyclosporine Treatment for Moderate to Severe Atopic Dermatitis: Analysis of the Spanish Atopic Dermatitis Registry (BIOBADATOP).
Couselo-Rodríguez C, Batalla A, Carrascosa JM, Chicharro P, González-Quesada A, de la Cueva P, Giménez-Arnau AM, Gilaberte Y, Rodríguez-Serna M, Montero-Vilchez T, Ruiz-Villaverde R, Elosua-González M, Silvestre-Salvador JF, Munera-Campos M, Sánchez-Pérez J, Carretero G, Mauleón-Fernández C, Curto-Barredo L, Ballano-Ruiz A, Botella-Estrada R, Arias-Santiago S, Navarro-Triviño FJ, Roustan-Gullón G, Betlloch I, Del Alcázar E, Abalde-Pintos MT, Suárez-Perez J, García-Doval I, Descalzo MÁ, Flórez Á. Couselo-Rodríguez C, et al. Among authors: carretero g. Actas Dermosifiliogr. 2024 Apr;115(4):341-346. doi: 10.1016/j.ad.2023.07.014. Epub 2023 Jul 22. Actas Dermosifiliogr. 2024. PMID: 37482292 Free article. English, Spanish.
Safety of biologic therapy in combination with methotrexate in moderate to severe psoriasis: a cohort study from the BIOBADADERM registry.
Lluch-Galcerá JJ, Carrascosa JM, González-Quesada A, Rivera-Díaz R, Sahuquillo-Torralba A, Llamas-Velasco M, Gómez-García FJ, Herrera-Acosta E, de la Cueva P, Baniandrés-Rodríguez O, Lopez-Estebaranz JL, Belinchón I, Ferrán M, Mateu A, Rodríguez L, Riera-Monroig J, Abalde-Pintos MT, Carretero G, García-Donoso C, Pujol-Marco C, Del Alcázar E, Santamaría-Domínguez C, Suárez-Pérez JA, Nieto-Benito LM, Ruiz-Genao DP, Salgado-Boquete L, Descalzo MÁ, García-Doval I. Lluch-Galcerá JJ, et al. Among authors: carretero g. Br J Dermatol. 2024 Feb 16;190(3):355-363. doi: 10.1093/bjd/ljad382. Br J Dermatol. 2024. PMID: 37846976
Transition to ustekinumab in patients with moderate-to-severe psoriasis and inadequate response to methotrexate: a randomized clinical trial (TRANSIT).
Paul C, Puig L, Kragballe K, Luger T, Lambert J, Chimenti S, Girolomoni G, Nicolas JF, Rizova E, Lavie F, Mistry S, Bergmans P, Barker J, Reich K; TRANSIT Investigators. Paul C, et al. Br J Dermatol. 2014 Feb;170(2):425-34. doi: 10.1111/bjd.12646. Br J Dermatol. 2014. PMID: 24116959 Free article. Clinical Trial.
Approach to the Epidemiology, Disease Management, and Current Challenges in the Management of Generalized Pustular Psoriasis Through a Survey Conducted Among Spanish Dermatologists.
Vilarrasa E, Rivera R, Eiris N, Carretero G, de la Cueva P, Carrascosa JM. Vilarrasa E, et al. Among authors: carretero g. Actas Dermosifiliogr. 2024 May;115(5):449-457. doi: 10.1016/j.ad.2023.10.022. Epub 2023 Nov 2. Actas Dermosifiliogr. 2024. PMID: 37925068 Free article. English, Spanish.
111 results